AVRO stock forecast
Our latest prediction for Avrobio, Inc.'s stock price was made on the July 19, 2019 when the stock price was at 21.99$.
In the short term (2weeks), AVRO's stock price should outperform the market by 5.59%. During that period the price should oscillate between -11.47% and +16.98%.
In the medium term (3months), AVRO's stock price should outperform the market by 4.20%. During that period the price should oscillate between -21.50% and +33.37%.Get email alerts
About Avrobio, Inc.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.27$ per share.
The book value per share is 4.42$
Three months stock forecastJuly 19, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|